<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="11" family="Helvetica-Black,Bold" color="#ffffff"/>
	<fontspec id="font1" size="8" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font2" size="8" family="AkzidenzGroteskBE-Md,Bold" color="#000000"/>
	<fontspec id="font3" size="8" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font4" size="8" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font5" size="2" family="AkzidenzGroteskBE" color="#ffffff"/>
	<fontspec id="font6" size="15" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font7" size="16" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font8" size="16" family="AkzidenzGroteskBE,BoldItalic" color="#000000"/>
	<fontspec id="font9" size="12" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font10" size="6" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font11" size="8" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font12" size="11" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font13" size="9" family="AkzidenzGroteskBE-Md,Bold" color="#000000"/>
	<fontspec id="font14" size="9" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font15" size="9" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font16" size="10" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font17" size="10" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
<text top="85" left="477" width="78" height="10" font="font0" id="p1_t1" reading_order_no="2" segment_no="1" tag_type="title"><a href="http://www.biomedcentral.com/info/about/charter/"><b>Open Access</b></a></text>
<text top="42" left="311" width="62" height="7" font="font1" id="p1_t2" reading_order_no="0" segment_no="0" tag_type="text"><b>Available online</b></text>
<text top="42" left="375" width="181" height="7" font="font3" id="p1_t3" reading_order_no="1" segment_no="0" tag_type="text">http://breast-cancer-research.com/content/7/1/R145</text>
<text top="735" left="569" width="19" height="8" font="font4" id="p1_t4" reading_order_no="130" segment_no="24" tag_type="text">R145</text>
<text top="85" left="57" width="9" height="2" font="font5" id="p1_t5" reading_order_no="4" segment_no="2" tag_type="title">Vol 7 No 1</text>
<text top="85" left="57" width="103" height="14" font="font6" id="p1_t6" reading_order_no="3" segment_no="2" tag_type="title">Research article</text>
<text top="102" left="57" width="455" height="14" font="font7" id="p1_t7" reading_order_no="5" segment_no="3" tag_type="title"><b>Alphavirus replicon particles containing the gene for HER2/</b></text>
<text top="102" left="512" width="33" height="14" font="font8" id="p1_t8" reading_order_no="6" segment_no="3" tag_type="title"><i><b>neu </b></i></text>
<text top="120" left="57" width="361" height="14" font="font7" id="p1_t9" reading_order_no="7" segment_no="3" tag_type="title"><b>inhibit breast cancer growth and tumorigenesis</b></text>
<text top="138" left="57" width="74" height="11" font="font9" id="p1_t10" reading_order_no="8" segment_no="4" tag_type="text">Xiaoyan Wang</text>
<text top="137" left="131" width="12" height="8" font="font3" id="p1_t11" reading_order_no="9" segment_no="4" tag_type="text">1,2</text>
<text top="138" left="143" width="86" height="11" font="font9" id="p1_t12" reading_order_no="10" segment_no="4" tag_type="text">, Jian-Ping Wang</text>
<text top="137" left="229" width="5" height="8" font="font3" id="p1_t13" reading_order_no="11" segment_no="4" tag_type="text">1</text>
<text top="138" left="234" width="111" height="11" font="font9" id="p1_t14" reading_order_no="12" segment_no="4" tag_type="text">, Maureen F Maughan</text>
<text top="137" left="345" width="5" height="8" font="font3" id="p1_t15" reading_order_no="13" segment_no="4" tag_type="text">3</text>
<text top="138" left="350" width="136" height="11" font="font9" id="p1_t16" reading_order_no="14" segment_no="4" tag_type="text"> and Lawrence B Lachman</text>
<text top="137" left="486" width="12" height="8" font="font3" id="p1_t17" reading_order_no="15" segment_no="4" tag_type="text">1,2</text>
<text top="171" left="57" width="3" height="5" font="font10" id="p1_t18" reading_order_no="16" segment_no="5" tag_type="text">1</text>
<text top="171" left="60" width="375" height="7" font="font3" id="p1_t19" reading_order_no="17" segment_no="5" tag_type="text">Department of Bioimmunotherapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA</text>
<text top="180" left="57" width="3" height="5" font="font10" id="p1_t20" reading_order_no="18" segment_no="6" tag_type="text">2</text>
<text top="181" left="60" width="398" height="7" font="font3" id="p1_t21" reading_order_no="19" segment_no="6" tag_type="text">The Graduate School of Biomedical Sciences, The University of Texas Health Sciences Center, Houston, Texas, USA</text>
<text top="190" left="57" width="3" height="5" font="font10" id="p1_t22" reading_order_no="20" segment_no="7" tag_type="text">3</text>
<text top="190" left="60" width="204" height="7" font="font3" id="p1_t23" reading_order_no="21" segment_no="7" tag_type="text">AlphaVax, Inc., Research Triangle Park, North Carolina, USA</text>
<text top="208" left="57" width="263" height="7" font="font3" id="p1_t24" reading_order_no="22" segment_no="8" tag_type="text">Corresponding author: Lawrence B Lachman, Lachman@odin.mdacc.tmc.edu</text>
<text top="226" left="57" width="481" height="7" font="font3" id="p1_t25" reading_order_no="23" segment_no="9" tag_type="text">Received: 1 Jul 2004 Revisions requested: 8 Sep 2004 Revisions received: 9 Sep 2004 Accepted: 13 Oct 2004 Published: 29 Nov 2004</text>
<text top="245" left="57" width="65" height="7" font="font11" id="p1_t26" reading_order_no="24" segment_no="10" tag_type="text"><i>Breast Cancer Res</i></text>
<text top="245" left="122" width="25" height="7" font="font3" id="p1_t27" reading_order_no="25" segment_no="10" tag_type="text"> 2005, </text>
<text top="245" left="147" width="4" height="7" font="font2" id="p1_t28" reading_order_no="26" segment_no="10" tag_type="text"><b>7</b></text>
<text top="245" left="152" width="124" height="7" font="font3" id="p1_t29" reading_order_no="27" segment_no="10" tag_type="text">:R145-R155 (DOI 10.1186/bcr962)</text>
<text top="249" left="276" width="45" height="2" font="font5" id="p1_t30" reading_order_no="28" segment_no="10" tag_type="text">http://breast-cancer-research.com/content/7/1/R145</text>
<text top="255" left="57" width="50" height="7" font="font3" id="p1_t31" reading_order_no="29" segment_no="11" tag_type="text">Â© 2004 Wang</text>
<text top="255" left="107" width="17" height="7" font="font11" id="p1_t32" reading_order_no="30" segment_no="11" tag_type="text"><i> et al</i></text>
<text top="255" left="124" width="107" height="7" font="font3" id="p1_t33" reading_order_no="31" segment_no="11" tag_type="text">., licensee BioMed Central Ltd. </text>
<text top="265" left="57" width="494" height="7" font="font3" id="p1_t34" reading_order_no="32" segment_no="12" tag_type="text">This is an Open Access article distributed under the terms of the Creative Commons Attribution License<a href="(http://creativecommons.org/licenses/by/2.0)"> (http://creativecommons.org/licenses/by/</a></text>
<text top="275" left="57" width="397" height="7" font="font3" id="p1_t35" reading_order_no="33" segment_no="12" tag_type="text"><a href="(http://creativecommons.org/licenses/by/2.0)">2.0)</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is cited.</text>
<text top="304" left="57" width="43" height="10" font="font12" id="p1_t36" reading_order_no="34" segment_no="13" tag_type="title"><b>Abstract</b></text>
<text top="325" left="57" width="49" height="8" font="font13" id="p1_t37" reading_order_no="35" segment_no="14" tag_type="text"><b>Introduction</b></text>
<text top="325" left="106" width="118" height="8" font="font14" id="p1_t38" reading_order_no="36" segment_no="14" tag_type="text"> Overexpression of the HER2/</text>
<text top="325" left="224" width="17" height="8" font="font15" id="p1_t39" reading_order_no="37" segment_no="14" tag_type="text"><i>neu </i></text>
<text top="325" left="241" width="56" height="8" font="font14" id="p1_t40" reading_order_no="38" segment_no="14" tag_type="text">gene in breast</text>
<text top="335" left="57" width="240" height="8" font="font14" id="p1_t41" reading_order_no="39" segment_no="14" tag_type="text">cancer is associated with an increased incidence of metastatic</text>
<text top="346" left="57" width="240" height="8" font="font14" id="p1_t42" reading_order_no="40" segment_no="14" tag_type="text">disease and with a poor prognosis. Although passive</text>
<text top="356" left="57" width="240" height="8" font="font14" id="p1_t43" reading_order_no="41" segment_no="14" tag_type="text">immunotherapy with the humanized monoclonal antibody</text>
<text top="367" left="57" width="240" height="8" font="font14" id="p1_t44" reading_order_no="42" segment_no="14" tag_type="text">trastuzumab (Herceptin) has shown some effect, a vaccine</text>
<text top="377" left="57" width="240" height="8" font="font14" id="p1_t45" reading_order_no="43" segment_no="14" tag_type="text">capable of inducing T-cell and humoral immunity could be more</text>
<text top="388" left="57" width="34" height="8" font="font14" id="p1_t46" reading_order_no="44" segment_no="14" tag_type="text">effective.</text>
<text top="409" left="57" width="36" height="8" font="font13" id="p1_t47" reading_order_no="45" segment_no="16" tag_type="text"><b>Methods</b></text>
<text top="409" left="92" width="205" height="8" font="font14" id="p1_t48" reading_order_no="46" segment_no="16" tag_type="text"> Virus-like replicon particles (VRP) of Venezuelan</text>
<text top="419" left="57" width="226" height="8" font="font14" id="p1_t49" reading_order_no="47" segment_no="16" tag_type="text">equine encephalitis virus containing the gene for HER2/</text>
<text top="419" left="283" width="14" height="8" font="font15" id="p1_t50" reading_order_no="48" segment_no="16" tag_type="text"><i>neu</i></text>
<text top="430" left="57" width="22" height="8" font="font14" id="p1_t51" reading_order_no="49" segment_no="16" tag_type="text">(VRP-</text>
<text top="430" left="79" width="14" height="8" font="font15" id="p1_t52" reading_order_no="50" segment_no="16" tag_type="text"><i>neu</i></text>
<text top="430" left="94" width="204" height="8" font="font14" id="p1_t53" reading_order_no="51" segment_no="16" tag_type="text">) were tested by an active immunotherapeutic</text>
<text top="440" left="57" width="240" height="8" font="font14" id="p1_t54" reading_order_no="52" segment_no="16" tag_type="text">approach in tumor prevention models and in a metastasis</text>
<text top="451" left="57" width="68" height="8" font="font14" id="p1_t55" reading_order_no="53" segment_no="16" tag_type="text">prevention model.</text>
<text top="325" left="315" width="31" height="8" font="font13" id="p1_t56" reading_order_no="54" segment_no="15" tag_type="text"><b>Results</b></text>
<text top="325" left="346" width="22" height="8" font="font14" id="p1_t57" reading_order_no="55" segment_no="15" tag_type="text"> VRP-</text>
<text top="325" left="368" width="17" height="8" font="font15" id="p1_t58" reading_order_no="56" segment_no="15" tag_type="text"><i>neu </i></text>
<text top="325" left="384" width="172" height="8" font="font14" id="p1_t59" reading_order_no="57" segment_no="15" tag_type="text">prevented or significantly inhibited the growth</text>
<text top="335" left="315" width="38" height="8" font="font14" id="p1_t60" reading_order_no="58" segment_no="15" tag_type="text">of HER2/</text>
<text top="335" left="353" width="14" height="8" font="font15" id="p1_t61" reading_order_no="59" segment_no="15" tag_type="text"><i>neu</i></text>
<text top="335" left="368" width="188" height="8" font="font14" id="p1_t62" reading_order_no="60" segment_no="15" tag_type="text">-expressing murine breast cancer cells injected</text>
<text top="346" left="315" width="241" height="8" font="font14" id="p1_t63" reading_order_no="61" segment_no="15" tag_type="text">either into mammary tissue or intravenously. Vaccination with</text>
<text top="356" left="315" width="20" height="8" font="font14" id="p1_t64" reading_order_no="62" segment_no="15" tag_type="text">VRP-</text>
<text top="356" left="335" width="17" height="8" font="font15" id="p1_t65" reading_order_no="63" segment_no="15" tag_type="text"><i>neu </i></text>
<text top="356" left="352" width="204" height="8" font="font14" id="p1_t66" reading_order_no="64" segment_no="15" tag_type="text">completely prevented tumor formation in and death of</text>
<text top="367" left="315" width="35" height="8" font="font14" id="p1_t67" reading_order_no="65" segment_no="15" tag_type="text">MMTV-c-</text>
<text top="367" left="350" width="17" height="8" font="font15" id="p1_t68" reading_order_no="66" segment_no="15" tag_type="text"><i>neu </i></text>
<text top="367" left="367" width="172" height="8" font="font14" id="p1_t69" reading_order_no="67" segment_no="15" tag_type="text">transgenic mice, and resulted in high levels of </text>
<text top="367" left="539" width="14" height="8" font="font15" id="p1_t70" reading_order_no="68" segment_no="15" tag_type="text"><i>neu</i></text>
<text top="367" left="553" width="3" height="8" font="font14" id="p1_t71" reading_order_no="69" segment_no="15" tag_type="text">-</text>
<text top="377" left="315" width="50" height="8" font="font14" id="p1_t72" reading_order_no="70" segment_no="15" tag_type="text">specific CD8</text>
<text top="377" left="366" width="6" height="6" font="font10" id="p1_t73" reading_order_no="71" segment_no="15" tag_type="text">+ </text>
<text top="377" left="372" width="116" height="8" font="font14" id="p1_t74" reading_order_no="72" segment_no="15" tag_type="text">T lymphocytes and serum IgG.</text>
<text top="430" left="315" width="46" height="8" font="font13" id="p1_t75" reading_order_no="73" segment_no="17" tag_type="text"><b>Conclusion</b></text>
<text top="430" left="361" width="195" height="8" font="font14" id="p1_t76" reading_order_no="74" segment_no="17" tag_type="text"> On the basis of these findings, clinical testing of</text>
<text top="440" left="315" width="150" height="8" font="font14" id="p1_t77" reading_order_no="75" segment_no="17" tag_type="text">this vaccine in patients with HER2/</text>
<text top="440" left="465" width="14" height="8" font="font15" id="p1_t78" reading_order_no="76" segment_no="17" tag_type="text"><i>neu</i></text>
<text top="440" left="480" width="6" height="6" font="font10" id="p1_t79" reading_order_no="77" segment_no="17" tag_type="text">+ </text>
<text top="440" left="488" width="68" height="8" font="font14" id="p1_t80" reading_order_no="78" segment_no="17" tag_type="text">breast cancer is</text>
<text top="451" left="315" width="40" height="8" font="font14" id="p1_t81" reading_order_no="79" segment_no="17" tag_type="text">warranted.</text>
<text top="472" left="57" width="40" height="7" font="font2" id="p1_t82" reading_order_no="80" segment_no="18" tag_type="text"><b>Keywords: </b></text>
<text top="472" left="97" width="315" height="7" font="font3" id="p1_t83" reading_order_no="81" segment_no="18" tag_type="text">adjuvant treatment, breast cancer, gene vaccines, immunotherapy, virus-like replicon particles</text>
<text top="511" left="57" width="64" height="10" font="font12" id="p1_t84" reading_order_no="82" segment_no="19" tag_type="title"><b>Introduction</b></text>
<text top="523" left="57" width="240" height="9" font="font16" id="p1_t85" reading_order_no="83" segment_no="21" tag_type="text">The management of breast cancer currently relies on sur-</text>
<text top="535" left="57" width="240" height="9" font="font16" id="p1_t86" reading_order_no="84" segment_no="21" tag_type="text">gery, chemotherapy and radiotherapy. Despite recent</text>
<text top="546" left="57" width="241" height="9" font="font16" id="p1_t87" reading_order_no="85" segment_no="21" tag_type="text">advances in clinical management of breast cancer once</text>
<text top="558" left="57" width="240" height="9" font="font16" id="p1_t88" reading_order_no="86" segment_no="21" tag_type="text">metastasis has occurred, the probability of a complete cure</text>
<text top="570" left="57" width="240" height="9" font="font16" id="p1_t89" reading_order_no="87" segment_no="21" tag_type="text">is greatly reduced. Of the women who have no detectable</text>
<text top="582" left="57" width="240" height="9" font="font16" id="p1_t90" reading_order_no="88" segment_no="21" tag_type="text">lymph node metastases at the time of diagnosis, up to one-</text>
<text top="593" left="57" width="240" height="9" font="font16" id="p1_t91" reading_order_no="89" segment_no="21" tag_type="text">third later develop metastases<a href=""> [1]. I</a>n patients with meta-</text>
<text top="605" left="57" width="240" height="9" font="font16" id="p1_t92" reading_order_no="90" segment_no="21" tag_type="text">static disease that does not respond to radiotherapy or</text>
<text top="617" left="57" width="240" height="9" font="font16" id="p1_t93" reading_order_no="91" segment_no="21" tag_type="text">chemotherapy, immunotherapy may offer an additional form</text>
<text top="629" left="57" width="240" height="9" font="font16" id="p1_t94" reading_order_no="92" segment_no="21" tag_type="text">of cancer co<a href="">ntrol [2-4</a>]. Clinical trials of trastuzumab, a</text>
<text top="640" left="57" width="166" height="9" font="font16" id="p1_t95" reading_order_no="93" segment_no="21" tag_type="text">monoclonal antibody specific for HER2/</text>
<text top="640" left="223" width="16" height="9" font="font17" id="p1_t96" reading_order_no="94" segment_no="21" tag_type="text"><i>neu</i></text>
<text top="640" left="239" width="59" height="9" font="font16" id="p1_t97" reading_order_no="95" segment_no="21" tag_type="text">, have demon-</text>
<text top="652" left="57" width="241" height="9" font="font16" id="p1_t98" reading_order_no="96" segment_no="21" tag_type="text">strated the utility of an immunologic approach for breast</text>
<text top="664" left="57" width="240" height="9" font="font16" id="p1_t99" reading_order_no="97" segment_no="21" tag_type="text">cancers that overexpress this gene [<a href="">5-7]. A drawbac</a>k to</text>
<text top="676" left="57" width="240" height="9" font="font16" id="p1_t100" reading_order_no="98" segment_no="21" tag_type="text">'passive' immunotherapy using monoclonal antibodies is</text>
<text top="687" left="57" width="241" height="9" font="font16" id="p1_t101" reading_order_no="99" segment_no="21" tag_type="text">that the effect is short-lived. An alternative approach is</text>
<text top="511" left="315" width="151" height="9" font="font16" id="p1_t102" reading_order_no="100" segment_no="20" tag_type="text">active vaccination that could induce </text>
<text top="511" left="466" width="16" height="9" font="font17" id="p1_t103" reading_order_no="101" segment_no="20" tag_type="text"><i>neu</i></text>
<text top="511" left="482" width="74" height="9" font="font16" id="p1_t104" reading_order_no="102" segment_no="20" tag_type="text">-specific cytotoxic</text>
<text top="523" left="315" width="240" height="9" font="font16" id="p1_t105" reading_order_no="103" segment_no="20" tag_type="text">T cells with the ability to control the growth of the primary</text>
<text top="535" left="315" width="240" height="9" font="font16" id="p1_t106" reading_order_no="104" segment_no="20" tag_type="text">tumor and metastases. However, unlike passive immuno-</text>
<text top="546" left="315" width="241" height="9" font="font16" id="p1_t107" reading_order_no="105" segment_no="20" tag_type="text">therapy whose effectiveness quickly wanes, effector and</text>
<text top="558" left="315" width="241" height="9" font="font16" id="p1_t108" reading_order_no="106" segment_no="20" tag_type="text">memory T cells induced by vaccination may remain present</text>
<text top="570" left="315" width="241" height="9" font="font16" id="p1_t109" reading_order_no="107" segment_no="20" tag_type="text">and be able to respond to any metastatic cells expressing</text>
<text top="582" left="315" width="28" height="9" font="font16" id="p1_t110" reading_order_no="108" segment_no="20" tag_type="text">HER2/</text>
<text top="582" left="344" width="18" height="9" font="font17" id="p1_t111" reading_order_no="109" segment_no="20" tag_type="text"><i>neu </i></text>
<text top="582" left="362" width="103" height="9" font="font16" id="p1_t112" reading_order_no="110" segment_no="20" tag_type="text">that arise after treatment.</text>
<text top="605" left="315" width="28" height="9" font="font16" id="p1_t113" reading_order_no="111" segment_no="22" tag_type="text">HER2/</text>
<text top="605" left="344" width="18" height="9" font="font17" id="p1_t114" reading_order_no="112" segment_no="22" tag_type="text"><i>neu </i></text>
<text top="605" left="364" width="192" height="9" font="font16" id="p1_t115" reading_order_no="113" segment_no="22" tag_type="text">is an excellent target for gene vaccines, and</text>
<text top="617" left="315" width="240" height="9" font="font16" id="p1_t116" reading_order_no="114" segment_no="22" tag_type="text">several preclinical studies have shown the effectiveness of</text>
<text top="629" left="315" width="117" height="9" font="font16" id="p1_t117" reading_order_no="115" segment_no="22" tag_type="text">plasmid vaccines encoding </text>
<text top="629" left="433" width="18" height="9" font="font17" id="p1_t118" reading_order_no="116" segment_no="22" tag_type="text"><i>neu </i></text>
<text top="629" left="452" width="104" height="9" font="font16" id="p1_t119" reading_order_no="117" segment_no="22" tag_type="text"><a href="">in murine models [8-16].</a></text>
<text top="640" left="315" width="241" height="9" font="font16" id="p1_t120" reading_order_no="118" segment_no="22" tag_type="text">Using a plasmid markedly different from those previously</text>
<text top="652" left="315" width="241" height="9" font="font16" id="p1_t121" reading_order_no="119" segment_no="22" tag_type="text">de<a href="">scribed [8-16], we created </a>an effective gene vaccine</text>
<text top="664" left="315" width="62" height="9" font="font16" id="p1_t122" reading_order_no="120" segment_no="22" tag_type="text">against HER2/</text>
<text top="664" left="377" width="18" height="9" font="font17" id="p1_t123" reading_order_no="121" segment_no="22" tag_type="text"><i>neu </i></text>
<text top="664" left="397" width="159" height="9" font="font16" id="p1_t124" reading_order_no="122" segment_no="22" tag_type="text"><a href="">[17]</a>. The previously described ELVIS</text>
<text top="676" left="315" width="161" height="9" font="font16" id="p1_t125" reading_order_no="123" segment_no="22" tag_type="text">plasmid vaccine construct for HER2/</text>
<text top="676" left="476" width="18" height="9" font="font17" id="p1_t126" reading_order_no="124" segment_no="22" tag_type="text"><i>neu </i></text>
<text top="676" left="497" width="59" height="9" font="font16" id="p1_t127" reading_order_no="125" segment_no="22" tag_type="text">contained the</text>
<text top="687" left="315" width="240" height="9" font="font16" id="p1_t128" reading_order_no="126" segment_no="22" tag_type="text">cDNA of a replicon RNA from the Alphavirus Sindbis</text>
<text top="714" left="57" width="499" height="7" font="font3" id="p1_t129" reading_order_no="127" segment_no="23" tag_type="footnote">BSA = bovine serum albumin; FACS = fluorescence-activated cell sorting; FCS = fetal calf serum; FITC = fluorescein isothiocyanate; HA = hemag-</text>
<text top="724" left="57" width="499" height="7" font="font3" id="p1_t130" reading_order_no="128" segment_no="23" tag_type="footnote">glutinin; IFN = interferon; IU = infectious units; MEM = modified Eagle's medium; MMTV = mouse mammary tumor virus; PBS = phosphate-buffered </text>
<text top="733" left="57" width="293" height="7" font="font3" id="p1_t131" reading_order_no="129" segment_no="23" tag_type="footnote">saline; VEE = Venezuelan equine encephalitis virus; VRP = virus-like replicon particles.</text>
</page>
</pdf2xml>
